Clinical Trial Update: Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating bortezomib in pediatric patients with refractory or recurrent leukemia, including blast-phase chronic myeloid leukemia, childhood acu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Childhood
• Acute Myeloid Leukemia Childhood
• Acute Promyelocytic Leukemia
• Chronic Myeloid Leukemia Blast Phase

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3) | Phase 1 | Status: COMPLETED